teplizumab 在新诊断 3 期 1 型糖尿病儿童青少年中保留 β 细胞功能:PROTECT 随机试验符合方案人群分析
基于 PROTECT 随机试验的符合方案(PP)人群分析,纳入 275 例 8–17 岁新诊断 3 期 1 型糖尿病受试者,比较 teplizumab 与安慰剂对 β 细胞功能的影响。第 78 周时,teplizumab 组刺激后 C 肽较基线的变化显著优于安慰剂(最小二乘均值差 0.14 nmol/l,95%CI 0.10–0.18,p<0.001),并显著降低外源胰岛素用量、提高葡萄糖目标范围内时间(TIR),且 β 细胞功能保留不受 HLA 亚型或基线自身抗体影响。
要点
- 第 78 周时 teplizumab 组刺激后 C 肽变化较安慰剂组高 0.14 nmol/l(95%CI 0.10–0.18,p<0.001)。
- teplizumab 显著降低外源胰岛素剂量并提高 TIR(最小二乘均值差 6.17%,95%CI 0.13–12.2,p<0.05)。
- β 细胞功能保留不受 HLA-DR3/HLA-DR4 或基线 1 型糖尿病自身抗体影响。
核心结论
- 按方案使用 teplizumab 可较安慰剂更好地保留 β 细胞功能、提高 TIR 并减少外源胰岛素用量。
- β 细胞功能保留不受 HLA 亚型或基线 1 型糖尿病自身抗体影响。
研究设计与样本
- PROTECT 随机试验的符合方案(PP)人群分析,年龄 8–17 岁、3 期 1 型糖尿病、刺激后 C 肽峰值≥0.2 nmol/l;ITT 人群 N=328。
- 按 2:1 随机接受两个 12 天疗程的静脉 teplizumab 或安慰剂。
- PP 人群共 275 例(teplizumab n=180,安慰剂 n=95);排除治疗依从性<80%、使用违禁药物、接受错误研究治疗或妊娠者。
- 亚组分析基于 HLA-DR3 或 HLA-DR4 存在情况及基线 1 型糖尿病自身抗体类型。
主要发现
- 第 78 周主要终点:teplizumab 与安慰剂之间刺激后 C 肽浓度较基线变化的最小二乘均值差为 0.14 nmol/l(95%CI 0.10–0.18;p<0.001)。
- 第 78 周外源胰岛素剂量最小二乘均值差为 −0.17 U kg⁻¹ day⁻¹(95%CI −0.26–−0.08;p<0.001)。
- 第 78 周 TIR 最小二乘均值差为 6.17%(95%CI 0.13–12.2;p<0.05)。
- 亚组分析中,无论 HLA-DR3/HLA-DR4 是否存在或基线 1 型糖尿病自身抗体如何,teplizumab 组 C 肽水平均高于安慰剂组。
临床怎么用
- 对新诊断 3 期 1 型糖尿病儿童青少年,teplizumab 可考虑用于保留 β 细胞功能并改善血糖管理指标。
- HLA 亚型或基线自身抗体状态不应作为排除 teplizumab 治疗的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: In the PROTECT randomised trial, teplizumab demonstrated significantly greater beta cell function preservation vs placebo in the intent-to-treat (ITT) population. Analyses of the pre-specified per-protocol (PP) population and PP subgroups are presented to further evaluate the efficacy of teplizumab. METHODS: Participants aged 8-17 years with stage 3 type 1 diabetes with a peak stimulated C-peptide level ≥0.2 nmol/l (ITT population: N=328) were randomised 2:1 to receive two 12-day courses of teplizumab or placebo intravenously. Participants with <80% treatment adherence, who took prohibited medication, received incorrect study treatment or were pregnant were excluded from the PP population. Subgroup analyses were based on the presence of HLA-DR3 or HLA-DR4 and the type of baseline type 1 diabetes autoantibodies. RESULTS: The PP population comprised 275 participants (teplizumab, n=180; placebo, n=95). At week 78, the primary endpoint of the least squares (LS) mean difference in change of stimulated C-peptide concentration from baseline between teplizumab and placebo was 0.14 nmol/l (95% CI 0.10, 0.18; p<0.001). At week 78, teplizumab treatment significantly reduced the exogenous insulin dose (LS mean difference -0.17 U kg-1 day-1; 95% CI -0.26, -0.08; p<0.001) and increased the time in range (TIR) (LS mean difference 6.17%; 95% CI 0.13, 12.2; p<0.05) vs placebo. In subgroup analyses, treatment with teplizumab resulted in higher C-peptide levels compared with placebo, regardless of HLA-DR3/HLA-DR4 presence or baseline type 1 diabetes autoantibodies. CONCLUSIONS/INTERPRETATION: Teplizumab treatment per protocol led to greater beta cell function preservation, greater TIR and lower exogenous insulin use compared with placebo. Beta cell function preservation was maintained irrespective of HLA subtype or the presence of type 1 diabetes autoantibodies. TRIAL REGISTRATION: ClinicalTrials.gov NCT03875729 FUNDING: The study was funded by Provention Bio, a Sanofi company.
引用
- Herold KC, Dayan CM, Chatenoud L, et al. Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial. Diabetologia. 2026. PMID: 42720752. doi:10.1007/s00125-026-06849-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。